<p>/PRNewswire/ -- Generate Biomedicines, Inc. (纳斯达克: GENB)（&#34;Generate&#34;），是一家处于临床阶段的生成生物学公司，正在引领生物技术和药物设计与开发中的人工智能革命，今天宣布其首次公开募股的定价为 2500 万股普通股，每股公开发行价格为 16.00 美元。预计此次发行的总收益为 4 亿美元，未扣除承销折扣和佣金以及 Generate 需支付的估计发行费用。此外，Generate 已授予承销商一个 30 天的选择权，以初始公开发行价格购买最多 375 万股，扣除承销折扣和佣金。所有股份均由 Generate 提供。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg"/></p>
<p>Generate 的普通股预计将于 2026 年 2 月 27 日在纳斯达克全球精选市场开始交易，股票代码为&#34;GENB&#34;。此次发行预计将于 2026 年 3 月 2 日完成，具体取决于惯例的交割条件。</p>
<p>高盛证券公司和摩根士丹利担任此次发行的联合主承销商。Piper Sandler、Guggenheim Securities 和 Cantor 担任此次发行的承销商。</p>
<p>与这些证券相关的注册声明已提交，并于 2026 年 2 月 26 日获得美国证券交易委员会的有效声明。此次发行仅通过招股说明书进行。最终招股说明书的副本在可用时可从高盛证券公司获取，联系人：招股说明书部门，地址：200 West Street, New York, NY 10282，电话：(866) 471-2526，传真：212 902-9316，或通过电子邮件：prospectus-ny@ny.email.gs.com；摩根士丹利，联系人：招股说明书部门，地址：180 Varick Street, 2nd Floor, New York, NY 10014；Piper Sandler &amp; Co.，联系人：招股说明书部门，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，电话：(800) 747-3924，或通过电子邮件：prospectus@psc.com；Guggenheim Securities, LLC，联系人：股权承销部门，地址：330 Madison Avenue, 8th Floor, New York, NY 10017，电话：(212) 518-9544，或通过电子邮件：GSEquityProspectusDelivery@guggenheimpartners.com；Cantor Fitzgerald &amp; Co.，联系人：资本市场，地址：110 East 59th Street, 6th Floor, New York, New York 10022，或通过电子邮件：prospectus@cantor.com。</p>
<p>本新闻稿不构成出售任何证券的要约，或购买任何证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的销售，若在该州或司法管辖区内的证券法下，此类要约、邀请或销售是非法的，需在注册或资格确认之前。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿包含某些披露，包含&#34;前瞻性声明&#34;，包括但不限于，关于 Generate 对其股票在纳斯达克全球精选市场开始交易的预期、发行的完成和交割时间以及预计的发行总收益的声明。前瞻性声明基于 Generate 当前的预期，并受到固有的不确定性、风险和假设的影响，这些因素难以预测。可能导致实际结果与预期不同的因素包括但不限于与市场条件、满足惯例交割条件和发行完成相关的风险和不确定性，以及制药产品开发和临床试验中固有的风险。这些及其他风险和不确定性在提交给证券交易委员会的注册声明的&#34;风险因素&#34;部分中有更全面的描述。本公告中包含的前瞻性声明截至本日期作出，Generate 不承担更新该信息的义务，除非适用法律要求。读者不应在本新闻稿发布后依赖其中的信息为当前或准确。</p>
<p><strong>Generate 联系方式</strong></p>
<p>梅根·麦克劳克林</p>
<p>pr@generatebiomedicines.com</p>
<p>来源：Generate:Biomedicines</p>

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

2 倍做空纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Generate Biomedicines, Inc. 宣布其首次公开募股（IPO）定价为每股 16.00 美元，共计 2500 万股，目标总收益为 4 亿美元。该股票将于 2026 年 2 月 27 日在纳斯达克交易，股票代码为 "GENB"，预计募股将在 2026 年 3 月 2 日结束。高盛和摩根士丹利是此次募股的主承销商。公司已向美国证券交易委员会（SEC）提交了注册声明，募股需遵循惯例的成交条件</p>

<p>, /PRNewswire/ -- Generate Biomedicines, Inc. (Nasdaq: GENB) (&#34;Generate&#34;), a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development, today announced the pricing of its initial public offering of 25,000,000 shares of common stock at a public offering price of $16.00 per share. The gross proceeds from the offering are expected to be $400 million, before underwriting discounts and commissions and estimated offering expenses payable by Generate. In addition, Generate has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares at the initial public offering price, less underwriting discounts and commissions. All shares are being offered by Generate.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Generate Biomedicines, Inc. (纳斯达克: GENB)（&#34;Generate&#34;），是一家处于临床阶段的生成生物学公司，正在引领生物技术和药物设计与开发中的人工智能革命，今天宣布其首次公开募股的定价为 2500 万股普通股，每股公开发行价格为 16.00 美元。预计此次发行的总收益为 4 亿美元，未扣除承销折扣和佣金以及 Generate 需支付的估计发行费用。此外，Generate 已授予承销商一个 30 天的选择权，以初始公开发行价格购买最多 375 万股，扣除承销折扣和佣金。所有股份均由 Generate 提供。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2594219/generate_bio_logo_rgb_black__3_Logo.jpg"/></p>
<p>Generate's common stock is expected to begin trading on the Nasdaq Global Select Market on February 27, 2026, under the ticker symbol &#34;GENB.&#34; The offering is expected to close on March 2, 2026, subject to customary closing conditions.</p>
<div class="lb-trans"><p>Generate 的普通股预计将于 2026 年 2 月 27 日在纳斯达克全球精选市场开始交易，股票代码为&#34;GENB&#34;。此次发行预计将于 2026 年 3 月 2 日完成，具体取决于惯例的交割条件。</p>
</div><p>Goldman Sachs &amp; Co. LLC and Morgan Stanley are acting as joint lead book-running managers for the offering. Piper Sandler, Guggenheim Securities, and Cantor are acting as book-running managers for the offering.</p>
<div class="lb-trans"><p>高盛证券公司和摩根士丹利担任此次发行的联合主承销商。Piper Sandler、Guggenheim Securities 和 Cantor 担任此次发行的承销商。</p>
</div><p>A registration statement relating to these securities has been filed and was declared effective by the U.S. Securities and Exchange Commission on February 26, 2026. This offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained from Goldman Sachs &amp; Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, via fax: 212 902-9316, or via email: prospectus-ny@ny.email.gs.com; Morgan Stanley &amp; Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Piper Sandler &amp; Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, MN 55401, by telephone at (800) 747-3924, or via email at prospectus@psc.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com; and Cantor Fitzgerald &amp; Co., Attention: Capital Markets, at 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.</p>
<div class="lb-trans"><p>与这些证券相关的注册声明已提交，并于 2026 年 2 月 26 日获得美国证券交易委员会的有效声明。此次发行仅通过招股说明书进行。最终招股说明书的副本在可用时可从高盛证券公司获取，联系人：招股说明书部门，地址：200 West Street, New York, NY 10282，电话：(866) 471-2526，传真：212 902-9316，或通过电子邮件：prospectus-ny@ny.email.gs.com；摩根士丹利，联系人：招股说明书部门，地址：180 Varick Street, 2nd Floor, New York, NY 10014；Piper Sandler &amp; Co.，联系人：招股说明书部门，地址：350 North 5th Street, Suite 1000, Minneapolis, MN 55401，电话：(800) 747-3924，或通过电子邮件：prospectus@psc.com；Guggenheim Securities, LLC，联系人：股权承销部门，地址：330 Madison Avenue, 8th Floor, New York, NY 10017，电话：(212) 518-9544，或通过电子邮件：GSEquityProspectusDelivery@guggenheimpartners.com；Cantor Fitzgerald &amp; Co.，联系人：资本市场，地址：110 East 59th Street, 6th Floor, New York, New York 10022，或通过电子邮件：prospectus@cantor.com。</p>
</div><p>This news release does not constitute an offer to sell, or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新闻稿不构成出售任何证券的要约，或购买任何证券的要约邀请，也不应在任何州或司法管辖区内进行这些证券的销售，若在该州或司法管辖区内的证券法下，此类要约、邀请或销售是非法的，需在注册或资格确认之前。</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>This press release includes certain disclosures that contain &#34;forward-looking statements,&#34; including, without limitation, statements regarding Generate's expectations regarding the commencement of trading of its shares on the Nasdaq Global Select Market, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are based on Generate's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to market conditions, the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in pharmaceutical product development and clinical trials. These and other risks and uncertainties are described more fully in the &#34;Risk Factors&#34; section of the registration statement filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Generate undertakes no duty to update such information except as required under applicable law. Readers should not rely upon the information in this press release as current or accurate after its publication date.</p>
<div class="lb-trans"><p>本新闻稿包含某些披露，包含&#34;前瞻性声明&#34;，包括但不限于，关于 Generate 对其股票在纳斯达克全球精选市场开始交易的预期、发行的完成和交割时间以及预计的发行总收益的声明。前瞻性声明基于 Generate 当前的预期，并受到固有的不确定性、风险和假设的影响，这些因素难以预测。可能导致实际结果与预期不同的因素包括但不限于与市场条件、满足惯例交割条件和发行完成相关的风险和不确定性，以及制药产品开发和临床试验中固有的风险。这些及其他风险和不确定性在提交给证券交易委员会的注册声明的&#34;风险因素&#34;部分中有更全面的描述。本公告中包含的前瞻性声明截至本日期作出，Generate 不承担更新该信息的义务，除非适用法律要求。读者不应在本新闻稿发布后依赖其中的信息为当前或准确。</p>
</div><p><strong>Generate Contact</strong></p>
<div class="lb-trans"><p><strong>Generate 联系方式</strong></p>
</div><p>Megan McLaughlin</p>
<div class="lb-trans"><p>梅根·麦克劳克林</p>
</div><p>pr@generatebiomedicines.com</p>
<div class="lb-trans"><p>pr@generatebiomedicines.com</p>
</div><p>SOURCE Generate:Biomedicines</p>
<div class="lb-trans"><p>来源：Generate:Biomedicines</p>
</div>

Generate Biomedicines, Inc. Announces Pricing of Initial Public Offering | GENB Stock News

StockTitan

Generate Biomedicines, Inc. 宣布首次公开募股的定价 | GENB 股票新闻